Join us at our first DDM Summit diring the UEG week in Berlin ! 🎉 Very excited to organize this meeting with M. Heikenwälder and F. Real. This new meeting format is designed for basic and translational scientists interested in GI tract diseases and cancer. 📍 Join us onsite in Room New York!

Eine große Aufgabe und Verantwortung! Ich freue mich sehr weiterhin als Senatsvorsitzende zusammen mit den Senatsmitglieder die MedUni mitgestalten zu dürfen. Danke für das grosse Vertrauen!

🎤 Meet Our Speaker: Dr. @maria-sibilia.bsky.social  , from Center for Cancer Research, Medical University of Vienna (Vienna, Austria) as a speaker at the Targeting RAS Symposium 2025. Dr. Sibilia will giver her talk during Session 10 on Day 3 at 11:15h.  🔗 https://targetingras.com/registration/

Our paper is now out with Cover! It reveals the specific role of EGFR in Ras mutant colorectal tumors which include metabolic rewiring, incresed stemness and more….all driven by Smoc2. have a look 👇👇🔝

Check out our new paper! We identified Smoc2 as an interesting target that is upregulated upon EGFR deletion, driving stemness signatures, reduction in cell size and metabolic rewiring. 💪 🔝👍

I am deeply enthusiastic about contributing to elevate this journal to the highest ranks #science #drugdiscovery #openaccess #biomedicalresearch #cancer #aging #neurology #genomics #precisionmedicine #Elsevier

Can metastatic cancer be outsmarted by using the body’s innate immune system? At #CIMT2025, @maria-sibilia.bsky.social will present translational insights from mechanisms to therapeutics—exploring how the innate immune system can be harnessed to fight metastatic disease. www.meeting.cimt.eu

Vienna: start 13.00 in front of the main University building 🔝 👏👏

Thank you for the great organisation ! @fusionconf.bsky.social

An exciting conference is just about to start 🔝💪👍 @fusionconf.bsky.social

Online now at Nature Cancer! @maria-sibilia.bsky.social and team propose a strategy to boost immunotherapy by combining topically applied TLR7/8 agonists with systemic interferon-I, sensitizing dendritic cells to produce IL-12 for tumor clearance 👇 www.nature.com/articles/s43...

1/2 News from the Sibilia Lab 🔔 🔝Very excited about our very recent publication in @Nature Cancer 🔝🔝where we describe a new immunotherapeutic approach to treat topically accessible tumors like melanoma and breast cancer with the TLR7/8 agonist Imiquimod in combination with systemic Interferon.

2/2 This combination therapy shows efficacy against local tumors and distant metastases and sensitizes tumors to checkpoint inhibitors with enhanced memory formation. Check out the cool mechanism in our paper ⬇️ 👇 rdcu.be/d7c4X

I am extremely honored and proud to be invited as a speaker to this historical meeting celebrating the „EGF-receptor after 40 years“ organized at the #Royal-Society in London by Marc A. Lemmon from #YaleUniversity. A fantastic line-up of great contributors to the EGFR field #MedicalUniversityVienna

Our joint paper with the lab of Thomas Bauer is out in EMBO Mol Med. check it out and admire our beautiful cover! www.embopress.org/journal/1757...

Very proud that Cristiano de Sa Fernandes received the Award of Excellence 2024 from the Austrian Ministry of Science for his PhD thesis performed in my laboratory on the „Role of Epigenetic modifications in Dendritic Cell Development and Function“. Congratulations, very well deserved 👏👏 #DC #cancer

A fantastic meeting #EMDS-2024 with lots of great speakers in a beautiful historical place #ÖAW in Vienna. Thanks to the organizers for putting together this great program. emds2024.com #DC #macrophages #myeloid-cells